Compare FOXF & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | RCKT |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.0M | 534.2M |
| IPO Year | 2013 | N/A |
| Metric | FOXF | RCKT |
|---|---|---|
| Price | $17.72 | $3.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $30.25 | $29.73 |
| AVG Volume (30 Days) | 493.8K | ★ 3.8M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | $64.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $2.19 |
| 52 Week High | $31.18 | $8.26 |
| Indicator | FOXF | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 41.22 |
| Support Level | $15.58 | $3.32 |
| Resistance Level | $18.21 | $4.08 |
| Average True Range (ATR) | 0.76 | 0.19 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 80.55 | 25.17 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.